Oruka Therapeutics (ORKA) Liabilities and Shareholders Equity (2010 - 2026)

Oruka Therapeutics has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $504.5 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 33.77% year-over-year to $504.5 million; the trailing twelve-month figure through Mar 2026 stood at $1.9 billion (up 52.31% YoY), and the FY2025 full-year result was $488.6 million, up 23.38% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $504.5 million, up from $488.6 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $509.3 million in Q3 2025, with the low at $33.8 million in Q2 2024.
• Average Liabilities and Shareholders Equity over 5 years is $203.8 million, with a median of $48.1 million recorded in 2022.
• Year-over-year, Liabilities and Shareholders Equity dropped 26.38% in 2022 and soared 956.78% in 2024.
• Tracing ORKA's Liabilities and Shareholders Equity over 5 years: stood at $43.1 million in 2022, then decreased by 12.12% to $37.9 million in 2023, then surged by 945.98% to $396.0 million in 2024, then grew by 23.38% to $488.6 million in 2025, then climbed by 3.25% to $504.5 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $504.5 million (Q1 2026), $488.6 million (Q4 2025), and $509.3 million (Q3 2025), per Business Quant data.

Peer Comparison